Lannett gets FDA nod for NumbrinoLannett expects to launch Numbrino nasal solution shortly. FDA report highlights 2019 drug approvalsTwenty-nine of the 48 novel drug approvals of 2019, or 60%, were designated in one or more expedited categories of Fast Track, Breakthrough, Priority Review, and/or Accelerated Approval. Daiichi Sankyo debuts Enhertu Enhertu is indicated for the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens. Allergan reaches $300M settlement in Loestrin, Minastrin suit Warner Chilcott and Watson subsidiaries will pay approximately $300 million under settlement agreements. Daiichi Sankyo obtains FDA approval for Enhertu Daiichi Sankyo's Enhertu provides a new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies. Allergan gets FDA OK for Ubrelvy Ubrelvy is the first and only oral calcitonin gene-related peptide receptor antagonist for the treatment of migraine attacks once they start. FDA approves expanded indication for Amarin’s Vascepa Vascepa was originally approved as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Ortho Dermatologics gets FDA green light for Arazlo Arazlo is the first FDA approved tazarotene acne treatment in a lotion formulation. Pfizer gets FDA nod for Xeljanz XR Pfizer's Xeljanz XR offers patients with moderately to severely active ulcerative colitis a once-daily dosing option. Cumberland gets FDA nod for RediTrex Cumberland's RediTrex injection is a treatment for adult and pediatric patients with rheumatoid arthritis, as well as adults with psoriasis. First Previous 31 32 33 34 35 Next Last